Audio roundup of selected biopharma industry content from Scrip over the business week ended Apr. 10, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time – Trump’s 100% tariffs and pharma; US tariffs loom over US-approved Chinese drugs; Gilead’s Tubulis buy-out; a closer look at Neurocrine’s Soleno bid; and an analysis of Q1 M&A.

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-O7KEIWGMHBCLZBHKJPKGHOZYPE/

Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman and Editor-in-Chief Nielsen Hobbs discuss the details of the US Food and Drug Administration’s labeling update for leucovorin (:41), including GSK’s subsequent move to re-withdraw the application (19:45). They also grade the tenure of Steve Ubl as he prepares to leave as Pharmaceutical Research and Manufacturers of America president and CEO (21:02) and consider what the organization may seek in its next leader (27:07).

#pharma #business

More On These Topics From The Pink Sheet

A Regulatory Pathway Of One: US FDA’s Wellcovorin Approval Would Be Hard To Scale: https://insights.citeline.com/pink-sheet/rare-diseases/a-regulatory-pathway-of-one-us-fdas-wellcovorin-approval-would-be-hard-to-scale-BHEAMFMG5BDJHJY5K6Z5OJF22A/

Israel has been a prolific source of biotech and AI-driven startups for years, but can it compete as a strategic R&D partner for global pharma? Mati Gill, CEO of AION Labs, makes the case that it can. AION's venture studio model brings together AstraZeneca, Merck KGaA, Pfizer and Teva under one roof to co-create AI-native drug discovery companies, and its portfolio is already producing results: CombinAbleAI, one of its startups, was acquired by insitro less than two years after it was founded. Gill talks about Israel's genuine strengths in science and technology, the structural gaps that still need closing, and why three years of operating through an active war may actually be a point in the ecosystem's favour for risk-conscious partners. Recorded, with some interruptions, from Tel Aviv.

Andrew Parker, CEO at Step Pharma, outlined the company’s “pipeline in a product” strategy as it seeks to develop a targeted approach to blood cancers and solid tumors by inhibiting CTSP1 enzyme. 

#clinicalstrategy #oncology

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年4月03日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 礼来收购Centessa的意义；Apellis为Biogen注入新能力；中国企业在肥胖症领域取得的快速进展；口服药物在肥胖症治疗中占据主导地位；以及全球制药研发管线规模的缩减。

Audio roundup of selected biopharma industry content from Scrip over the business week ended Apr. 3, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time – what Lilly’s Centessa buy brings; Apellis brings capabilities to Biogen: Chinese firms’ rapid obesity progress; orals take center stage in obesity; and a dip in the global pharma pipeline.  

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-HFN7H2ELQBBRHHFQQ2AYFBMXNM/

In this episode of the China biopharma English-language podcast, Xu Hu

The Pink Sheet stories related to this episode:

CAR-T Guidelines Signal China’s Next

CAR-Ts Win Big In New China Drug

A legal firm’s perspective on how the UK should evolve its medtech regulatory system, global harmonization and opportunities to embed best practice AI.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年3月27当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 默克公司力推Terns及其他交易；勃林格殷格翰对欧洲创新环境不佳的警示；科伦与默克的协议如何改变了中国的交易格局；神经科学研发重振旗鼓；以及美国新的低密度脂蛋白胆固醇（LDL-C）指南与药物成本。

In this episode of HBW Insight’s Over the Counter, we’re digging into one of the most talked‑about themes in consumer health right now: longevity.